GAMMA Investing’s AN2 Therapeutics ANTX Stock Holding History

GAMMA Investing’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.02K	Buy	+191	New	+$1.01K	﹤0.01%	4094

Other funds holding ANTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

GAMMA Investing's ANTX Position: Q3 2026 in Review

GAMMA Investing opened a new position in AN2 Therapeutics (ANTX) in Q3 2026: 191 shares worth $1.02K. The stake represents ﹤0.01% of the portfolio and ranks #4094 among its holdings.

19 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

GAMMA Investing held 191 shares of AN2 Therapeutics worth $1.02K as of Q3 2026.
AN2 Therapeutics was a new GAMMA Investing position in Q3 2026.
AN2 Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4094 holding.
19 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.